SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph II
Status:
Recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
A significant number of patients with malignant pleural mesothelioma (MPM) and non-small cell
lung cancer (NSCLC) are not cured with available treatments and will eventually relapse.
After relapse treatment options are limited. Preclinical in vitro studies have demonstrated a
synergism of immunotherapy with PD(L)1-targeting monoclonal antibodies and gemcitabine and
ongoing clinical studies showed encouraging results.
The main objective of this trial is to determine the efficacy of chemotherapy (gemcitabine)
combined with immunotherapy (atezolizumab) in patients with progressive NSCLC and MPM.
The trial treatments will be continued for max. 2 years or until discontinuation criteria are
met. The follow-up phase will last up to 5 years from treatment start.